

Standing Orders for the Medical Management of Neurologically Deceased Organ Donors - Pediatrics

Thamer Alaifan, Bram Rochwerg, Ian Ball, Laura Hornby, Lindsay Wilson, Sam Shemie

This order set for organ donor management is based on the updated 2020 Canadian Blood Services guideline [1]. Of note, unless indicated by asterisk (*), all recommendations are conditional and based on low or very low certainty of evidence and as such may not be applied in all scenarios or for every patient depending on situational factors and the best judgement of the clinician.

It is important to optimize multi-organ function to improve organ utilization and transplant outcomes. Attentive ICU management and re-evaluation can improve reversible organ dysfunction (myocardial and cardiovascular dysfunction, oxygenation impairment related to potentially reversible lung injury, invasive bacterial infections, hypernatremia and other metabolic abnormalities) and evaluate temporal trends in hepatic aspartate aminotransferase (AST), alanine aminotransferase (ALT) and creatinine or any other potentially treatable situation. This period of donor management should be accompanied by frequent re-evaluation to assess for improvement in organ function toward defined targets prior to surgical recovery of organs for transplant.

These orders apply to newborns to 18-year-olds and are intended for care provided within a pediatric ICU. Dose recommendations apply to children \leq 60 kg; for children > 60 kg, adult dosing should apply.

Standard monitoring	 Arterial line continuous blood pressure monitoring Pulse oximetry, 3-lead ECG Vital signs at least every hour Core temperature (rectal, bladder or esophageal) every 4 h Urine catheter to straight drainage, strict intake and output Nasogastric tube to straight drainage
Laboratory investigations	 Arterial blood gases, lactate, electrolytes and glucose every 6 h, and as needed Complete blood counts every 12 h, and as needed Blood urea nitrogen, creatinine, AST, ALT, bilirubin (total and direct), INR (or PT) and PTT every 12 h and as needed Urine analysis
Hemodynamic monitoring and therapy	 General targets: Adhere to age-related norms for pulse and blood pressure In case of age-related hypotension and/or shock: Hold short acting blood pressure lowering agents Fluid resuscitation to maintain normovolemia. Consider serum lactate and/or mixed venous/central venous oximetry; titrate therapy to MVO₂≥ 60%
Agents for hemodynamic support	 First line: Vasopressin: 2 to 2.4 U per h (0.04 U per min) Second line: Norepinephrine 0.05 to 0.1 mcg/kg per min Consider hydrocortisone 50mg IV every 6 h Additional vasopressors or inotropes depending on etiology (epinephrine, phenylephrine, dobutamine or milrinone)



Glycemia and nutrition Initiate enteral feeding (unless contra-indicated) or continue as tolerated, hold on call to the operating room If unable to tolerate enteral feeds, consider intravenous dextrose infusions Continue parenteral nutrition if already initiated prior to declaration Maintain serum glucose levels in the range of 6-10 mmol/L Fluid and electrolyte targets Waintain normal ranges for potassium, calcium, magnesium, phosphate Defined as: O Urine output > 4 mL/kg per h associated with Rising serum sodium ≥ 145 mmol/L and/or Rising serum osmolarity ≥ 300 mosM and/or Deraesing urine osmolarity ≥ 300 mosM and/or Dering hemodynamic stability: Intravenous vasopressin infusion 0.003–0.0007 U/kg per minute (0.3-0.7 mU/kg/minute) to a maximum dose of 2.4 U/h During hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3-0.7 mU/kg/minute) to a maximum dose of 2.4 U/h During hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3-0.7 mU/kg/minute) to a maximum dose of 2.4 U/h During hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3-0.7 mU/kg/minute) to a maximum dose of 2.4 U/h Routine thyroid hormone therapy is not recommended. Routine thyroid hormone therapy can be considered in cases of cardiac dysfunction or hemodynamic instability (Tetraiodthyronine (T4): 20 µg IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 25–50 µg IV every 12h) Routine infusion of combined solutions of glucose, insulin and potas		Avoid the use of dopamine at any dose
Bydemia and nutrition If unable to iolerate enteral feeds, consider intravenous dextrose infusions Continue parenteral nutrition if already initiated prior to declaration Maintain serum glucose levels in the range of 6-10 mmol/L Fluid and electrolyte targets Urine output goal 0.5–3 mL/kg per h Serum Na target 135-155 mmol/L Maintain normal ranges for potassium, calcium, magnesium, phosphate Diabetes insipidus Drine output > 4 mL/kg per h associated with Rising serum osmolarity ≥ 300 mosM and/or Decreasing urine osmolarity ≥ 200 mosM Diabetes insipidus Therapy (to be titrated to urine output ≤ 3 mL/kg per h): During hemodynamic stability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h During hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h During hemodynamic instability (Tetraiodthyronine (T4): 20 µg IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 10 µg/h		
nutrition In Unable to Industry endows for the edsy, considered intraventous education in the edition of a declaration Fluid and electrolyte targets Urine output goal 0.5–3 mL/kg per h Serum Na target 133-155 mmol/L Maintain normal ranges for potassium, calcium, magnesium, phosphate Defined as: 0 Urine output > 4 mL/kg per h associated with 0 Rising serum sodium ≥ 145 mmol/L and/or 0 Rising serum osmolarity ≥ 300 mosM and/or 0 Decreasing urine osmolarity ≥ 300 mosM and/or 0 During hemodynamic stability: 0 During hemodynamic stability: 0 During hemodynamic instability: 0 During hemodynamic inst		
• Continue parenteral nutrition if already initiated prior to declaration • Maintain serum glucose levels in the range of 6-10 mmol/L • Urine output goal 0.5–3 mL/kg per h • Serum Na target 135-155 mmol/L • Maintain normal ranges for potassium, calcium, magnesium, phosphate • Defined as: • Urine output > 4 mL/kg per h associated with • Rising serum sodium ≥ 145 mmol/L and/or • Rising serum somolarity ≥ 300 mosM and/or • Decreasing urine osmolarity ≥ 300 mosM and/or • Detrined as: • Urine output > 4 mL/kg per h associated with • Rising serum sodium ≥ 145 mmol/L and/or • Rising serum osmolarity ≥ 300 mosM and/or • Dering hemodynamic stability: • Uring hemodynamic stability: • Intravenous vasopressin infusion 0.003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • During hemodynamic instability: Intravenous vasopressin infusion 0.003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • During hemodynamic instability (Tetraidothyronine (T4): 20 µg IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 25–50 µg IV every 12h) • Routine thyroid hormone therapy is not recommended. • Routine infusion of combined solutions of glucose, insulin and potassium (GIK) is not recommended • Transfuse packed red blood cells (PR		 If unable to tolerate enteral feeds, consider intravenous dextrose infusions
Fluid and electrolyte targets • Urine output goal 0.5–3 mL/kg per h Serum Na target 135-155 mmol/L • Maintain normal ranges for potassium, calcium, magnesium, phosphate • Defined as: • Orine output > 4 mL/kg per h associated with • Rising serum sodium ≥ 145 mmol/L and/or • Rising serum cosmolarity ≥ 300 mosM and/or • Decreasing urine osmolarity ≥ 100 mosM • Therapy (to be titrated to urine output ≤ 3 mL/kg per h): • During hemodynamic stability: • Intravenous vasopressin infusion 0.003–0.0007 U/kg per minute (0.3– • 0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • During hemodynamic instability: Intravenous vasopressin infusion 0.003– 0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • During hemodynamic instability: Intravenous vasopressin infusion 0.003– 0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • During hemodynamic instability (Tetraidothyronine (T4): 20 Ug IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 25–50 µg IV every 12h) • Routine high dose corticosteroid is not recommended. • Routine high dose corticosteroid is not recommended. • Routine high dose corticosteroid is not recommended. • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packet PRN when clinicc		 Continue parenteral nutrition if already initiated prior to declaration
Prute and electrolyte targets Serum Na target 135-155 mmol/L Maintain normal ranges for potassium, calcium, magnesium, phosphate Defined as: Urine output > 4 mL/kg per h associated with Rising serum sodium ≥ 145 mmol/L and/or Rising serum somolarity ≥ 300 mosM and/or Decreasing urine osmolarity ≥ 300 mosM Therapy (to be titrated to urine output ≤ 3 mL/kg per h): During hemodynamic stability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h During hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h During hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h During hemodynamic instability (Tetraiodothyronine (T4): 20 µg IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 25–50 µg IV every 12h)		 Maintain serum glucose levels in the range of 6-10 mmol/L
electrolyte targets • Serum Na target 135-155 mmo//L Maintain normal ranges for potassium, calcium, magnesium, phosphate • Defined as: • Urine output > 4 mL/kg per h associated with • Rising serum osmolarity ≥ 300 mosM and/or • Decreasing urine osmolarity ≥ 200 mosM • Diabetes insipidus • Therapy (to be titrated to urine output 5 3 mL/kg per h): • During hemodynamic stability: • Intermittent DDAVP: 0.25-1 µg IV every 6 h (there is no true upper limit for dose; should be titrate to desired urine output rate) • Intravenous vasopressin infusion 0.00030.0007 U/kg per minute (0.3-0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • During hemodynamic instability: Intravenous vasopressin infusion 0.003-0.0007 U/kg per minute (0.3-0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • Outing thyroid hormone therapy is not recommended, unless otherwise indicated or recommended. Thyroid hormone therapy can be considered in cases of cardiac dysfunction or hemodynamic instability (Tretraiodothyronine (T4): 20 µg IV bolus followed by 10 µg/h IV infusion (or 50-100 µg IV bolus followed by 25-50 µg IV every 12h) • Routine high dose corticosteroid is not recommended. • Routine infusion of combined solutions of glucose, insulin and potassium (GIK) is not recommended • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L <th rowspan="3"></th> <th> Urine output goal 0.5–3 mL/kg per h </th>		 Urine output goal 0.5–3 mL/kg per h
Hematology Performed as: Outrine output > 4 mL/kg per h associated with Rising serum sodium ≥ 145 mmol/L and/or Diabetes insipidus Diabetes insipidus Diabetes insipidus Primetry (to be titrated to urine output 5 3 mL/kg per h): Ouring hemodynamic stability: Intermittent DDAVP: 0.25–1 µg IV every 6 h (there is no true upper limit for dose; should be titrated to desired urine output rate) Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h Ouring hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h Ohron During hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h Routine thyroid hormone therapy is not recommended, unless otherwise indicated or recommended. Thyroid hormone therapy can be considered in cases of cardiac dysfunction or hemodynamic instability: Intravenous vasopressim (GIK) is not recommended. Routine high dose corticosteroid is not recommended. Routine infusion of combined solutions of glucose, insulin and potassium (GIK) is not recommended. Routine infusion of combined solutions of glucose, insulin and potassium (GIK) is not recommended. Routine infusion of combined solutions of glucose, insulin and potassium (GIK) is not recommended.		
• Urine output > 4 mL/kg per h associated with • Rising serum sodium ≥ 145 mmol/L and/or • Rising serum osmolarity ≤ 300 mosM and/or • Decreasing urine osmolarity ≤ 200 mosM • Therapy (to be titrated to urine output ≤ 3 mL/kg per h): • During hemodynamic stability: • Intermittent DDAVP: 0.25–1 µg IV every 6 h (there is no true upper limit for dose; should be titrated to desired urine output rate) • Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3-0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • During hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3-0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • During hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3-0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • During hemodynamic instability: Intravenous vasopressin infusion 0.003–0.0007 U/kg per minute (0.3-0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • During hemodynamic instability: Intravenous vasopressin infusion 0.003–0.0007 U/kg per minute (0.3-0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • During hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per limit for dose corticosteriol is not recommended. • Routine hiyn dose corticosteroid is not recommended. • Routine infusion of combined solutions of glucose, insulin and potassium (GIK) is not recommended • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L <t< td=""><td></td></t<>		
• Rising serum sodium ≥ 145 mmol/L and/or • Rising serum osmolarity ≥ 300 mosM and/or • Rising serum osmolarity ≤ 300 mosM • Therapy (to be titrated to urine output ≤ 3 mL/kg per h): • Intermittent DDAVP: 0.25–1 µg IV every 6 h (there is no true upper limit for dose; should be titrated to desired urine output rate) • Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • During hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • Routine thyroid hormone therapy is not recommended, unless otherwise indicated or recommended. Thyroid hormone therapy can be considered in cases of cardiac dysfunction or hemodynamic instability (Tetraiodothyronine (T4): 20 µg IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 25–50 µg IV every 12h) • Routine influsion of combined solutions of glucose, insulin and potassium (GIK) is not recommended • Transfuse platelets to target above 10 x 10 ⁹ /L or in cases of clinically relevant bleeding • Transfuse platelets to target above 10 x 10 ⁹ /L or in cases of clinically relevant bleeding. • No other specific transfusion requirements • Initial screening blood, urine, and endotracheal tube culture • Repeat cultures PRN when clinically indicated • Continue antibiotics started before neurological determination of death • Administer antibiotics started before neurological determination of		
• Rising serum osmolarity ≥ 300 mosM and/or • Decreasing urine osmolarity ≤200 mosM • Therapy (to be titrated to urine output ≤ 3 mL/kg per h): • During hemodynamic stability: • Intermittent DDAVP: 0.25–1 µg IV every 6 h (there is no true upper limit for dose; should be titrated to desired urine output rate) • Intermittent DDAVP: 0.25–1 µg IV every 6 h (there is no true upper limit for dose; should be titrated to desired urine output rate) • Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • During hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • During hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • During hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • During hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • Routine thyroid hormone therapy can be considered in cases of cardiac dysfunction or hemodynamic instability (Tetraiodothyronine (T4): 20 µg IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 25–50 µg IV every 12h) • Routine infusion of combined solutions of glucose, insulin and potassium (GIK) is not recommended. • Routine infusion of combined solutions of glucose, insulin and potassi		
• Decreasing urine osmolarity ≤200 mosM • Therapy (to be titrated to urine output ≤ 3 mL/kg per h): • Uring hemodynamic stability: • Intermittent DDAVP: 0.25–1 µg IV every 6 h (there is no true upper limit for dose; should be titrated to desired urine output rate) • Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • During hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • During hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • During hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • Routine thyroid hormone therapy is not recommended, unless otherwise indicated or recommended. Thyroid hormone therapy can be considered in cases of cardiac dysfunction or hemodynamic instability (Tetraidothyronine (T4): 20 µg IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 25–50 µg IV every 12h) • Routine high dose corticosteroid is not recommended. • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g		
Diabetes insipidus Therapy (to be titrated to urine output ≤ 3 mL/kg per h): During hemodynamic stability:		
Diabetes insipidus • During hemodynamic stability: • Intermittent DDAVP: 0.25–1 µg IV every 6 h (there is no true upper limit for dose; should be titrated to desired urine output rate) • Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • During hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • Outing hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • Outing themodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • Outing themodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • Outing themodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • Outing themodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • Routine thyroid hormone therapy is not recommended, unless otherwise indicated or recommended. Thyroid hormone therapy is not recommended. • Routine infusion of combined solutions of glucose, insulin and potassium (GIK) is not recommended • Routine infusion of combined solutions of glucose, insulin and potassium (GIK) is not recommended • Transfuse platelets to target above 10 x 10 ⁹ /L		
Hematology Hematology Microbiology Microbiology Microbiology Heart-specific orders (to be Microbiology • Intermittent DDAVP: 0.25–1 µg IV every 6 h (there is no true upper limit for dose; should be titrated to desired urine output rate) • Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • During hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • Other thyroid hormone therapy is not recommended, unless otherwise indicated or recommended. Thyroid hormone therapy can be considered in cases of cardiac dysfunction or hemodynamic instability (Tetraiodothyronine (T4): 20 µg IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 25–50 µg IV every 12h) • Routine high dose corticosteroid is not recommended. • Routine infusion of combined solutions of glucose, insulin and potassium (GIK) is not recommended • Transfuse platelets to target above 10 x 10%L or in cases of clinically relevant bleeding. • No other specific transfusion requirements • Initial screening blood, urine, and endotracheal tube culture • Repeat cultures PRN when clinically indicated • Continue antibiotics only for presumed or proven infection and not prophylactically • 12-lead electrocardiogram • 2-dimensional echo		
Hermatology intrastrespecific orders (to be intravenous vasopressin infusion 0.003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h During hemodynamic instability: Intravenous vasopressin infusion 0.003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h During hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h Routine thyroid hormone therapy is not recommended, unless otherwise indicated or recommended. Thyroid hormone therapy can be considered in cases of cardiac dysfunction or hemodynamic instability (Tetraiodothyronine (T4): 20 µg IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 25–50 µg IV every 12h) Routine high dose corticosteroid is not recommended. Routine infusion of combined solutions of glucose, insulin and potassium (GIK) is not recommended Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L Transfuse platelets to target above 10 x 10%/L or in cases of clinically relevant bleeding. No other specific transfusion requirements Initial screening blood, urine, and endotracheal tube culture Repeat cultures PRN when clinically indicated Continue antibiotics started before neurological determination of death Administer antibiotics only for presumed or proven infection and not prophylactically 12-lead electrocardiogram! 2-dimensional echoccardiogramphy Consider repoat (ergin) echocardiography as clinically indicated o	Diabetes insipidus	
Hermatology Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h During hemodynamic instability: Intravenous vasopressin infusion 0.0003–0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h Routine thyroid hormone therapy is not recommended, unless otherwise indicated or recommended. Thyroid hormone therapy can be considered in cases of cardiac dysfunction or hemodynamic instability (Tetraiodothyronine (T4): 20 µg IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 25–50 µg IV every 12h) Routine high dose corticosteroid is not recommended. Routine infusion of combined solutions of glucose, insulin and potassium (GIK) is not recommended Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L Transfuse platelets to target above 10 x 10⁹/L or in cases of clinically relevant bleeding. No other specific transfusion requirements Initial screening blood, urine, and endotracheal tube culture Repeat cultures PRN when clinically indicated Constitue antibiotics started before neurological determination of death Administer antibiotics only for presumed or proven infection and not prophylactically 12-lead electrocardiogram 2-dimensional echocardiography Consider repeat (equil) echocardiography Consider repeat (equil) echocardiography Consider repeat (equil) echocardiography 	-	
0.7 mU/kg/minute) to a maximum dose of 2.4 U/h • During hemodynamic instability: Intravenous vasopressin infusion 0.0003– 0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h Routine thyroid hormone therapy is not recommended, unless otherwise indicated or recommended. Thyroid hormone therapy can be considered in cases of cardiac dysfunction or hemodynamic instability (Tetraiodothyronine (T4): 20 µg IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 25–50 µg IV every 12h) • Routine high dose corticosteroid is not recommended. • Routine infusion of combined solutions of glucose, insulin and potassium (GIK) is not recommended • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • There are no predefined targets for INR, PTT; avoid transfusion of fresh frozen plasma unless in cases of clinically relevant bleeding. • No other specific transfusion requirements • Initial screening blood, urine, and endotracheal tube culture • Repeat cultures PRN when clinically indicated • Consider anibiotics started before neurological determination of death • Administer antibiotics only for presumed or proven infection and not prophylactically • 12-lead electrocardiogram • 2-dimensional echocardiography orders (to be		
• During hemodynamic instability: Intravenous vasopressin infusion 0.0003– 0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h Routine thyroid hormone therapy is not recommended, unless otherwise indicated or recommended. Thyroid hormone therapy can be considered in cases of cardiac dysfunction or hemodynamic instability (Tetraiodothyronine (T4): 20 µg IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 25–50 µg IV every 12h) • Routine high dose corticosteroid is not recommended. • Routine infusion of combined solutions of glucose, insulin and potassium (GIK) is not recommended • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse platelets to target above 10 x 10 ⁹ /L or in cases of clinically relevant bleeding • There are no predefined targets for INR, PTT; avoid transfusion of fresh frozen plasma unless in cases of clinically relevant bleeding. • No other specific transfusion requirements • Initial screening blood, urine, and endotracheal tube culture • Repeat cultures PRN when clinically indicated Continue antibiotics started before neurological determination of death • Administer antibiotics only for presumed or proven infection and not prophylactically • 12-lead electrocardiogram • 2-dimensional echocardiography • 2-dimensional echocardiography • 0 • 12-lead electrocardiography • 0		
Hormonal therapy 0.0007 U/kg per minute (0.3–0.7 mU/kg/minute) to a maximum dose of 2.4 U/h Routine thyroid hormone therapy is not recommended, unless otherwise indicated or recommended. Thyroid hormone therapy can be considered in cases of cardiac dysfunction or hemodynamic instability (Tetraiodothyronine (T4): 20 µg IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 25–50 µg IV every 12h) • Routine high dose corticosteroid is not recommended. • Routine infusion of combined solutions of glucose, insulin and potassium (GIK) is not recommended • Routine infusion of combined solutions of glucose, insulin and potassium (GIK) is not recommended • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse patelets to target above 10 x 10 ⁹ /L or in cases of clinically relevant bleeding • There are no predefined targets for INR, PTT; avoid transfusion of fresh frozen plasma unless in cases of clinically relevant bleeding. • No other specific transfusion requirements • Initial screening blood, urine, and endotracheal tube culture • Repeat cultures PRN when clinically indicated • Continue antibiotics started before neurological determination of death • Administer antibiotics only for presumed or proven infection and not prophylactically • 12-lead electrocardiogramh • 2-lead electrocardiogramh • Continue antibiotics or proper infection and not prophylactically		
U/h Routine thyroid hormone therapy is not recommended, unless otherwise indicated or recommended. Thyroid hormone therapy can be considered in cases of cardiac dysfunction or hemodynamic instability (Tetraiodothyronine (T4): 20 µg IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 25–50 µg IV every 12h) • Routine high dose corticosteroid is not recommended. • Routine infusion of combined solutions of glucose, insulin and potassium (GIK) is not recommended • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • There are no predefined targets for INR, PTT; avoid transfusion of fresh frozen plasma unless in cases of clinically relevant bleeding. • No other specific transfusion requirements • Initial screening blood, urine, and endotracheal tube culture • Repeat cultures PRN when clinically indicated • Continue antibiotics started before neurological determinati		
Hormonal therapy Routine thyroid hormone therapy is not recommended, unless otherwise indicated or recommended. Thyroid hormone therapy can be considered in cases of cardiac dysfunction or hemodynamic instability (Tetraiodothyronine (T4): 20 µg IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 25–50 µg IV every 12h) • Routine high dose corticosteroid is not recommended. • Routine high dose corticosteroid is not recommended. • Routine infusion of combined solutions of glucose, insulin and potassium (GIK) is not recommended • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse platelets to target above 10 x 10 ⁹ /L or in cases of clinically relevant bleeding • There are no predefined targets for INR, PTT; avoid transfusion of fresh frozen plasma unless in cases of clinically relevant bleeding. • No other specific transfusion requirements • Initial screening blood, urine, and endotracheal tube culture • Repeat cultures PRN when clinically indicated • Continue antibiotics only for presumed or proven infection and not prophylactically • 12-lead electrocardiogram <th></th> <td></td>		
Hormonal therapy recommended. Thyroid hormone therapy can be considered in cases of cardiac dysfunction or hemodynamic instability (Tetraiodothyronine (T4): 20 µg IV bolus followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 25–50 µg IV every 12h) • Routine high dose corticosteroid is not recommended. • Routine infusion of combined solutions of glucose, insulin and potassium (GIK) is not recommended • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse packed red blood, urine, and endotracheal tube cellup. • No other specific transfusion requirements • Initial screening blood, urine, and endotracheal tube culture • Repeat cultures PRN when clinically indicated • Continue antibiotics started before neurological determination of death • Administer antibiotics only for presumed or proven infection and not prophylactically		
Hormonal therapy followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 25–50 µg IV every 12h) • Routine high dose corticosteroid is not recommended. • Routine infusion of combined solutions of glucose, insulin and potassium (GIK) is not recommended • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse platelets to target above 10 x 10 ⁹ /L or in cases of clinically relevant bleeding • There are no predefined targets for INR, PTT; avoid transfusion of fresh frozen plasma unless in cases of clinically relevant bleeding. • No other specific transfusion requirements • Initial screening blood, urine, and endotracheal tube culture • Repeat cultures PRN when clinically indicated • Continue antibiotics started before neurological determination of death • Administer antibiotics only for presumed or proven infection and not prophylactically Heart-specific orders (to be • 12-lead electrocardiogram • 2-dimensional echocardiography		
Hormonal therapy 12h) • Routine high dose corticosteroid is not recommended. • Routine infusion of combined solutions of glucose, insulin and potassium (GIK) is not recommended • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse platelets to target above 10 x 10 ⁹ /L or in cases of clinically relevant bleeding • There are no predefined targets for INR, PTT; avoid transfusion of fresh frozen plasma unless in cases of clinically relevant bleeding. • No other specific transfusion requirements • Initial screening blood, urine, and endotracheal tube culture • Repeat cultures PRN when clinically indicated • Continue antibiotics only for presumed or proven infection and not prophylactically • 12-lead electrocardiogram • 2-dimensional echocardiography • Consider repeat (serial) echocardiography		dysfunction or hemodynamic instability (Tetraiodothyronine (T4): 20 µg IV bolus
Hematology I211) • Routine high dose corticosteroid is not recommended. • Routine infusion of combined solutions of glucose, insulin and potassium (GIK) is not recommended • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse platelets to target above 10 x 10 ⁹ /L or in cases of clinically relevant bleeding • There are no predefined targets for INR, PTT; avoid transfusion of fresh frozen plasma unless in cases of clinically relevant bleeding. • No other specific transfusion requirements • Initial screening blood, urine, and endotracheal tube culture • Repeat cultures PRN when clinically indicated • Continue antibiotics started before neurological determination of death • Administer antibiotics only for presumed or proven infection and not prophylactically • 12-lead electrocardiogram • 2-dimensional echocardiography • Consider repeat (serial) echocardiography	Hormonal thereas	followed by 10 µg/h IV infusion (or 50–100 µg IV bolus followed by 25–50 µg IV every
• Routine infusion of combined solutions of glucose, insulin and potassium (GIK) is not recommended • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse platelets to target above 10 x 10 ⁹ /L or in cases of clinically relevant bleeding • There are no predefined targets for INR, PTT; avoid transfusion of fresh frozen plasma unless in cases of clinically relevant bleeding. • No other specific transfusion requirements • Initial screening blood, urine, and endotracheal tube culture • Repeat cultures PRN when clinically indicated • Continue antibiotics started before neurological determination of death • Administer antibiotics only for presumed or proven infection and not prophylactically • 12-lead electrocardiogram • 2-dimensional echocardiography • Consider repeat (cerial) echocardiography	поппонаі шегару	
Hematology • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse platelets to target above 10 x 10 ⁹ /L or in cases of clinically relevant bleeding • There are no predefined targets for INR, PTT; avoid transfusion of fresh frozen plasma unless in cases of clinically relevant bleeding. • No other specific transfusion requirements • Initial screening blood, urine, and endotracheal tube culture • Repeat cultures PRN when clinically indicated • Continue antibiotics started before neurological determination of death • Administer antibiotics only for presumed or proven infection and not prophylactically • 12-lead electrocardiogram • 2-dimensional echocardiography • Consider repeat (cerial) achocardiography		•
Hematology • Transfuse packed red blood cells (PRBC) for target Hb >= 70 g/L • Transfuse platelets to target above 10 x 10 ⁹ /L or in cases of clinically relevant bleeding • There are no predefined targets for INR, PTT; avoid transfusion of fresh frozen plasma unless in cases of clinically relevant bleeding. • No other specific transfusion requirements • Initial screening blood, urine, and endotracheal tube culture • Repeat cultures PRN when clinically indicated • Continue antibiotics started before neurological determination of death • Administer antibiotics only for presumed or proven infection and not prophylactically • 12-lead electrocardiogram • 2-dimensional echocardiography • Consider repeat (serial) echocardiography		
Hematology Transfuse platelets to target above 10 x 10⁹/L or in cases of clinically relevant bleeding. There are no predefined targets for INR, PTT; avoid transfusion of fresh frozen plasma unless in cases of clinically relevant bleeding. No other specific transfusion requirements Initial screening blood, urine, and endotracheal tube culture Repeat cultures PRN when clinically indicated Continue antibiotics started before neurological determination of death Administer antibiotics only for presumed or proven infection and not prophylactically 12-lead electrocardiogram 2-dimensional echocardiography Consider repeat (serial) echocardiography as clinically indicated or 		
Hematology bleeding • There are no predefined targets for INR, PTT; avoid transfusion of fresh frozen plasma unless in cases of clinically relevant bleeding. • No other specific transfusion requirements • Initial screening blood, urine, and endotracheal tube culture • Repeat cultures PRN when clinically indicated • Continue antibiotics started before neurological determination of death • Administer antibiotics only for presumed or proven infection and not prophylactically • 12-lead electrocardiogram • 2-dimensional echocardiography • Consider repeat (serial) echocardiography		
Hematology • There are no predefined targets for INR, PTT; avoid transfusion of fresh frozen plasma unless in cases of clinically relevant bleeding. • No other specific transfusion requirements • Initial screening blood, urine, and endotracheal tube culture • Repeat cultures PRN when clinically indicated • Continue antibiotics started before neurological determination of death • Administer antibiotics only for presumed or proven infection and not prophylactically • 12-lead electrocardiogram • 2-dimensional echocardiography • Consider repeat (serial) echocardiography as clinically indicated or	Hematology	
 Microbiology Microbiology Initial screening blood, urine, and endotracheal tube culture Repeat cultures PRN when clinically indicated Continue antibiotics started before neurological determination of death Administer antibiotics only for presumed or proven infection and not prophylactically 12-lead electrocardiogram 2-dimensional echocardiography Consider repeat (serial) echocardiography as clinically indicated or 		0
 No other specific transfusion requirements Initial screening blood, urine, and endotracheal tube culture Repeat cultures PRN when clinically indicated Continue antibiotics started before neurological determination of death Administer antibiotics only for presumed or proven infection and not prophylactically 12-lead electrocardiogram 2-dimensional echocardiography Consider repeat (serial) echocardiography as clinically indicated or 		
 Initial screening blood, urine, and endotracheal tube culture Repeat cultures PRN when clinically indicated Continue antibiotics started before neurological determination of death Administer antibiotics only for presumed or proven infection and not prophylactically Heart-specific orders (to be Consider repeat (serial) echocardiography as clinically indicated or 		
 Repeat cultures PRN when clinically indicated Continue antibiotics started before neurological determination of death Administer antibiotics only for presumed or proven infection and not prophylactically Heart-specific orders (to be Consider repeat (serial) echocardiography as clinically indicated or 	Microbiology	
Microbiology • Continue antibiotics started before neurological determination of death • Administer antibiotics only for presumed or proven infection and not prophylactically • Heart-specific orders (to be • Consider repeat (serial) echocardiography • Consider repeat (serial) echocardiography as clinically indicated or		
 Administer antibiotics only for presumed or proven infection and not prophylactically Heart-specific orders (to be Consider repeat (serial) echocardiography as clinically indicated or 		
prophylactically Heart-specific orders (to be 12-lead electrocardiogram 2-dimensional echocardiography 2-dimensional echocardiography	Microbiology	0
 Heart-specific orders (to be 12-lead electrocardiogram 2-dimensional echocardiography Consider repeat (serial) echocardiography as clinically indicated or 		
• 2-dimensional echocardiography		
orders (to be Consider repeat (serial) echocardiography as clinically indicated or	-	9
initiated in recommended	initiated in	
	orders (to be	2-dimensional echocardiography



potential heart donors)	 Should only be performed after fluid and hemodynamic resuscitation
Lung-specific orders	 Mechanical ventilation (**): Target tidal volumes: 6-8 mL/kg, and PEEP≥ 8 cm H₂O Target pH: 7.35–7.45, PaCO₂: 35–45 mmHg, PaO₂: ≥80 mmHg, O₂ saturation: ≥ 95% Recruitment maneuvers should be done upon ventilator disconnect (**): preoxygenation with 100% FiO₂ CPAP to 30 cm H₂O of PEEP for 30 seconds return FiO₂ to previous FiO₂ Use diuresis to target normovolemia Single routine chest radiograph should be done at baseline, additional chest imaging only as clinically indicated At least one-time bronchoscopy with gram stain and culture of bronchial wash
Intra-abdominal organs- specific	 If kidneys are considered, target goal core temperature between 34°C and 35°C Can target normothermia if kidneys are excluded Test urine for albumin/creatinine ratio (ACR) only when investigating donor with type I or type II diabetes mellitus Consider abdominal imaging ultrasound or CT abdomen according to local criteria

References

[1] Ball I, Hornby L, Rochwerg B, et al. Management of the neurologically deceased organ donor: A Canadian clinical practice guideline. *CMAJ* 2020 April 6;192:E361-9. doi: 10.1503/cmaj.190631